Skip to content

Study · Non-randomized trial · 1992

3 results

Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study.

McCormick PA, Biagini MR, Dick R, Greenslade L, Chin J, Cardin F, Wagstaff D, McIntyre N, Burroughs AK

Hepatology (Baltimore, Md.)1 Nov 1992Cited by 59 (Europe PMC)

PMID1427656 (opens in a new tab)DOI10.1002/hep.1840160513 (opens in a new tab)PepBankPUB-01427656
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In cirrhotic patients with portal hypertension, octreotide reduced azygos flow from 499 +/- 65 to 355 +/- 47 ml/min (p < 0.01).

    In plain wordsIn cirrhotic patients, octreotide reduced azygos blood flow from baseline.

    Peptide
    Octreotide
    Outcome
    DecreaseAzygos blood flow
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean azygos blood flow
    499 ml/min
    before octreotide (+/- 65)
    Mean azygos blood flow
    355 ml/min
    after octreotide (+/- 47)

    Source sentences

    Summary
    Octreotide significantly reduced azygos blood flow from a mean of 499 +/- 65 ml/min to a mean of 355 +/- 47 ml/min (p < 0.01)
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled study, we investigated the effects of octreotide on the hepatic venous pressures and azygos blood flow of 21 patients before and after a standard liquid meal containing 40 gm of protein in 250 ml.
  2. 02HumanNon-randomized trialEfficacy outcome

    In cirrhotic patients with portal hypertension, octreotide had no effect on the hepatic venous pressure gradient.

    In plain wordsIn cirrhotic patients, octreotide did not change the hepatic venous pressure gradient.

    Peptide
    Octreotide
    Outcome
    No significant changeHepatic venous pressure gradient
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but it had no effect on the hepatic venous pressure gradient.
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled study, we investigated the effects of octreotide on the hepatic venous pressures and azygos blood flow of 21 patients before and after a standard liquid meal containing 40 gm of protein in 250 ml.
  3. 03HumanNon-randomized trialEfficacy outcome

    In cirrhotic patients receiving octreotide, the hepatic venous pressure gradient did not change significantly during 2 hr after a meal.

    In plain wordsIn cirrhotic patients receiving octreotide, the hepatic venous pressure gradient did not change significantly after a meal.

    Peptide
    Octreotide
    Outcome
    No significant changePostprandial hepatic venous pressure gradient
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but the group receiving octreotide showed no significant changes during the 2 hr of observation.
    2 context sentences
    Summary · context
    In a second protocol hepatic venous pressures were measured in 20 patients at 30-min intervals for 2 hr after ingestion of the mixed meal.
    Summary · context
    In a double-blind, placebo-controlled study, we investigated the effects of octreotide on the hepatic venous pressures and azygos blood flow of 21 patients before and after a standard liquid meal containing 40 gm of protein in 250 ml.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.